PARP1 and cancer: Synthetic lethality is a novel paradigm in cancer treatment regimens that combines a cancer-inherent genetic mutation (such as BRCA1 or BRCA2 mutation) with the pharmacological inhibition of a specific molecular target (such as PARP1) [27,28].